[Federal Register: November 29, 2002 (Volume 67, Number 230)]
[Notices]
[Page 71180-71181]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29no02-94]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Backbone-Substituted Bifunctional DOTA Ligands, Complexes and
Compositions Thereof, and Methods of Using the Same
Martin Brechbiel, Hyun-soon Chung (NCI), DHHS Reference No. E-035-2002
filed 06 Sep 2002, Licensing Contact: Matthew Kiser; 301/435-5236;
kiserm@od.nih.gov.
The subject technology is directed to three backbone-substituted
1,4,7,10-tetraazacyclododecane (DOTA) compounds. These compounds can be
[[Page 71181]]
chelated with radionuclides and used as imaging or therapeutic agents.
In particular, the compounds can be complexed with a paramagnetic
element (e.g. Gd (III)) and used as contrast agents in magnetic
resonance imaging (MRI) applications.
The DOTA derivatives of the invention are such that the macrocyclic
backbone was pre-arranged or pre-organized in order to lower the energy
barrier to complex formation, thereby potentially increasing the rate
of complex formation. The pre-organization and macrocyclic effect of
the DOTA sub-structure accelerates complexation with metal ions and
isotopes (e.g. Y (III), Gd (III); etc.), while maintaining a high level
of stability of the complexes.
Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by
Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract
Raj K. Puri et al. (FDA), PCT application PCT/US02/00616, which claims
priority to U.S. Provisional Patent Application 60/337,179 (E-296-01/0)
filed December 4, 2001, Licensing Contact: Brenda Hefti; 301/435-4632;
heftib@od.nih.gov.
This invention relates to the alleviation of symptoms of Th2-like
cytokine mediated disorders, such as allergy, asthma, and to
hyperinflammatory responses in the respiratory tract to infectious
diseases and parasitic infections, including tuberculosis,
schistosomiasis, leishmania, and filiarsis.
This invention claims a variety of methods and uses of a chimeric
molecule comprising a toxic moiety and a targeting moiety that
specifically binds to a cell surface receptor for IL-13, to alleviate
symptoms of a variety of respiratory disorders. This method has been
proven successful in various mouse models in vivo.
Use of Mx GTPases in the Prognosis and Treatment of Cancer
J. Frederic Mushinski, Jane B. Trepel, Michel Andre Horisberger,
PhuongMai Nguyen, Chand Khanna (NCI), DHHS Reference No. E-292-01/0
filed 18 Oct 2001, Licensing Contact: Matthew Kiser; 301/435-5236;
kiserm@od.nih.gov.
The present invention describes novel approaches in the diagnosis,
reduction of progression and treatment of cancer using Mx GTPases (Mxs)
and Mx-encoding nucleic acids. The diagnostic benefits of this
invention include methods of assessing the metastatic potential of
cancer cells by determining the level of an Mx or Mx-encoding nucleic
acid present in the cells. This invention also provides a method for
administration of an Mx or expression of a nucleic acid encoding an Mx
at, in, or near cancer cells, as well as a method for systemic
induction of an Mx protein to reduce cancer progression in both solid
tumors and hematologic malignancies.
Use of a Promoter of T-Cell Expansion and an Inducer of CD40
Stimulation in the Treatment or Prevention of a Pathologic State
William J. Murphy, Robert Wiltrout, Bruce Blazar, Susan E. Wilson
(NCI), DHHS Reference Nos. E-150-01/0 filed 23 Aug 2001 and E-150-01/1
filed 23 Aug 2002, Licensing Contact: Matthew Kiser; 301/435-5236;
kiserm@od.nih.gov.
The present invention provides a method for the prevention and
treatment of pathologic states in mammals by administering a promoter
of T-cell expansion with an inducer of CD40 stimulation in
synergistically effective amounts. The disclosed invention could
provide treatments for cancers, viral infections, HIV, bacterial
infections, fungal infections, and allergic conditions. A method for
assessing the treatment administered is also described.
Dated: November 19, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 02-30227 Filed 11-27-02; 8:45 am]
BILLING CODE 4140-01-P